Cargando…

Acute Myeloid Leukemia: A Concise Review

Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure. Cytogenetics and mutation testing remain a critical prognostic tool for post induction treatment. Despite rapid advances in the field including new drug targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Saultz, Jennifer N., Garzon, Ramiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810104/
https://www.ncbi.nlm.nih.gov/pubmed/26959069
http://dx.doi.org/10.3390/jcm5030033
_version_ 1782423725551910912
author Saultz, Jennifer N.
Garzon, Ramiro
author_facet Saultz, Jennifer N.
Garzon, Ramiro
author_sort Saultz, Jennifer N.
collection PubMed
description Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure. Cytogenetics and mutation testing remain a critical prognostic tool for post induction treatment. Despite rapid advances in the field including new drug targets and increased understanding of the biology, AML treatment remains unchanged for the past three decades with the majority of patients eventually relapsing and dying of the disease. Allogenic transplant remains the best chance for cure for patients with intermediate or high risk disease. In this review, we discuss the landmark genetic studies that have improved outcome prediction and novel therapies.
format Online
Article
Text
id pubmed-4810104
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-48101042016-04-04 Acute Myeloid Leukemia: A Concise Review Saultz, Jennifer N. Garzon, Ramiro J Clin Med Review Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure. Cytogenetics and mutation testing remain a critical prognostic tool for post induction treatment. Despite rapid advances in the field including new drug targets and increased understanding of the biology, AML treatment remains unchanged for the past three decades with the majority of patients eventually relapsing and dying of the disease. Allogenic transplant remains the best chance for cure for patients with intermediate or high risk disease. In this review, we discuss the landmark genetic studies that have improved outcome prediction and novel therapies. MDPI 2016-03-05 /pmc/articles/PMC4810104/ /pubmed/26959069 http://dx.doi.org/10.3390/jcm5030033 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Saultz, Jennifer N.
Garzon, Ramiro
Acute Myeloid Leukemia: A Concise Review
title Acute Myeloid Leukemia: A Concise Review
title_full Acute Myeloid Leukemia: A Concise Review
title_fullStr Acute Myeloid Leukemia: A Concise Review
title_full_unstemmed Acute Myeloid Leukemia: A Concise Review
title_short Acute Myeloid Leukemia: A Concise Review
title_sort acute myeloid leukemia: a concise review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810104/
https://www.ncbi.nlm.nih.gov/pubmed/26959069
http://dx.doi.org/10.3390/jcm5030033
work_keys_str_mv AT saultzjennifern acutemyeloidleukemiaaconcisereview
AT garzonramiro acutemyeloidleukemiaaconcisereview